Climb Bio says CLYM116 Phase 1 data show ~29-day half-life in IgA nephropathy
Single 320 mg CLYM116 dose drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks, with ~29-day half-life. Treatment was generally well-tolerated with no serious AEs, dose-limiting toxicities or hypogammaglobulinemia.
Climb Bio said a single 320 mg dose of CLYM116 produced a ~29-day half-life and drove near-complete APRIL suppression, with 60-75% IgA/Gd-IgA1 suppression through 12 weeks. The company said CLYM116 was generally well tolerated, with no serious adverse events, dose-limiting toxicities or hypogammaglobulinemia. Climb Bio also referenced the Phase 2 NAVIGATE-2 trial in IgA nephropathy on…